NEW BRUNSWICK, N.J.,
Oct. 12, 2021 /PRNewswire/ -- Johnson
& Johnson (NYSE: JNJ) today announced the appointment of
Jessica Moore to Vice President of
Investor Relations for Johnson & Johnson, effective
November 1, 2021. Ms. Moore will
report to Mr. Joseph Wolk, Executive
Vice President and Chief Financial Officer of the Company.
Ms. Moore brings 20 years of strong, diverse and international
financial experience spanning across Sales Operations, Corporate
and Regional positions. Most recently, Ms. Moore served as the Vice
President and Chief Financial Officer for the Janssen
Pharmaceutical business in the EMEA Region where she played a
critical role in the analysis of financial performance, assessment
of risks and opportunities and maintenance of a strong compliant
environment. Prior to joining Johnson & Johnson, Ms. Moore held
various leadership positions of increasing responsibilities at
Baxter International, where she focused on returning the EMEA
business to growth and led a transformational project to
standardize and centralize financial processes across commercial
and manufacturing entities.
"Jessica's knowledge of our business and industries positions
her well to convey Johnson & Johnson's strategies and outcomes
to the investment community and other key stakeholders," said Mr.
Wolk. "Her dedication to innovative solutions and commitment to
talent development will have a positive impact across all aspects
of our business."
Ms. Moore holds a bachelor's degree in Finance and Accounting
from Miami (of Ohio) University and an
MBA from the Kellogg School of Management at Northwestern University.
About Johnson & Johnson
At Johnson & Johnson,
we believe good health is the foundation of vibrant lives, thriving
communities and forward progress. That's why for more than 130
years, we have aimed to keep people well at every age and every
stage of life. Today, as the world's largest and most broadly-based
health care company, we are committed to using our reach and size
for good. We strive to improve access and affordability, create
healthier communities, and put a healthy mind, body and environment
within reach of everyone, everywhere. We are blending our heart,
science and ingenuity to profoundly change the trajectory of health
for humanity.
Note to Investors Concerning Forward-Looking
Statements
This press release contains "forward-looking
statements" as defined in the Private Securities Litigation Reform
Act of 1995 regarding, among other things: future operating and
financial performance, product development, market position and
business strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: risks related to the impact of the
COVID-19 global pandemic, such as the scope and duration of the
outbreak, government actions and restrictive measures implemented
in response, material delays and cancellations of medical
procedures, supply chain disruptions and other impacts to the
business, or on the Company's ability to execute business
continuity plans, as a result of the COVID-19 pandemic, economic
factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent
in new product research and development, including uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the
Company to successfully execute strategic plans; the impact of
business combinations and divestitures; manufacturing difficulties
or delays, internally or within the supply chain; product efficacy
or safety concerns resulting in product recalls or regulatory
action; significant adverse litigation or government action,
including related to product liability claims; changes to
applicable laws and regulations, including tax laws and global
health care reforms; trends toward health care cost containment;
changes in behavior and spending patterns of purchasers of health
care products and services; financial instability of international
economies and legal systems and sovereign risk; increased scrutiny
of the health care industry by government agencies. A further list
and descriptions of these risks, uncertainties and other factors
can be found in Johnson & Johnson's Annual Report on
Form 10-K for the fiscal year ended January 3,
2021 including in the sections captioned "Cautionary Note
Regarding Forward-Looking Statements" and "Item 1A. Risk Factors,"
in the Company's most recently filed Quarterly Report on Form 10-Q
and the Company's subsequent filings with the Securities and
Exchange Commission. Copies of these filings are available online
at www.sec.gov, www.jnj.com or on request
from Johnson & Johnson. Any forward-looking statement made
in this release speaks only as of the date of this
release. Johnson & Johnson does not undertake to
update any forward-looking statement as a result of new information
or future events or developments.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-announces-jessica-moore-as-vice-president-of-investor-relations-301398394.html
SOURCE Johnson & Johnson